The unprecedented scale of the ongoing COVID-19 pandemic has catalyzed an intense
effort of the global scientific community to unravel different aspects of the disease in a short …

The genus Enterovirus (EV) of the family Picornaviridae includes poliovirus,
coxsackieviruses, echoviruses, numbered enteroviruses and rhinoviruses. These diverse …

The RNA-dependent RNA polymerase of the severe acute respiratory syndrome coronavirus
2 is an important target in current drug development efforts for the treatment of coronavirus …

Effective treatments for coronavirus disease 2019 (COVID-19) are urgently needed to control
this current pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS …

Abstract Aims In December 2019, the Coronavirus disease-2019 (COVID-19) virus has
emerged in Wuhan, China. In this research, the first resolved COVID-19 crystal structure …

Remdesivir (RDV), a broadly acting nucleoside analogue, is the only FDA approved small
molecule antiviral for the treatment of COVID-19 patients. To date, there are no reports …

The rapid global emergence of SARS-CoV-2 has been the cause of significant health
concern, highlighting the immediate need for antivirals. Viral RNA-dependent RNA …

Emerging coronaviruses (CoVs) cause severe disease in humans, but no approved
therapeutics are available. The CoV nsp14 exoribonuclease (ExoN) has complicated …

Eight different compounds, all nucleoside analogues, could presently be considered as
potential drug candidates for the treatment of Ebola virus (EBOV) and/or other hemorrhagic …

Coronaviruses (CoVs) stand out among RNA viruses because of their unusually large
genomes (∼ 30 kb) associated with low mutation rates. CoVs code for nsp14, a bifunctional …